Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 6/20 | 0.42 |
| ▸ | RXRA | P19793 | 2/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.39 |
| ▸ | PTGER3 | P43115 | 4/20 | 0.39 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15942232 | 0.92 | RXRA (0.47) | PTGER1RXRARXRBRXRGPTGER4 | |
| SCHEMBL15947712 | 0.92 | RXRA (0.47) | PTGER1RXRARXRBRXRGPTGER4 | |
| SCHEMBL15942231 | 0.92 | RXRA (0.47) | PTGER1RXRARXRBRXRGPTGER4 | |
| SCHEMBL17402231 | 0.84 | RXRA (0.47) | PTGER1RXRARXRBRXRGPTGER4 | |
| SCHEMBL15941028 | 0.83 | RXRA (0.49) | PTGER1RXRARXRBRXRGPTGER4 | |
| SCHEMBL15942310 | 0.83 | RXRA (0.49) | PTGER1RXRARXRBRXRGPTGER4 | |
| SCHEMBL15941208 | 0.83 | RXRA (0.49) | PTGER1RXRARXRBRXRGPTGER4 | |
| SCHEMBL15942243 | 0.83 | RXRA (0.49) | PTGER1RXRARXRBRXRGPTGER4 | |
| SCHEMBL17389334 | 0.83 | RXRA (0.49) | PTGER1RXRARXRBRXRGPTGER4 | |
| SCHEMBL17389349 | 0.80 | RXRA (0.44) | PTGER1RXRARXRBRXRGPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11149046-B2 | Antibacterial sideromycins | Hsiri Therapeutics, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| US-20190352691-A1 | PATHOGEN DETECTION | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2019-11-21 | — | — | US | disclosed |
| US-20190153010-A1 | ANTIBACTERIAL SIDEROMYCINS | Hsiri Therapeutics, LLC | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11149046-B2 | Antibacterial sideromycins | SLC40A1, SFXN1, SLC39A14 | PTGER1 4537/4885RXRA 3286/4885RXRB 3391/4885 |
| US-20190153010-A1 | ANTIBACTERIAL SIDEROMYCINS | SLC40A1, SFXN1, SLC39A14 | PTGER1 4537/4885RXRA 3286/4885RXRB 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.